PD-	3!	56	1 -	0	1	-JT
	~.	~~		~	-	01

CONVENTION APPLICATION BY A COMPANY	
FORM 8 - REGULATION 12 (2)	
AUSTRALIA	
ΡΑΤΕΝΤΟ ΔΟΤ 1952	

DECLARATION IN SUPPORT OF A CONVENTION APPLICATION FOR A PATENT

(a) Here Insert (in full) Name of Company.

In support of the Convention Application made by (a) WARNER-LAMBERT COMPANY

(b) Here insert Title of

(c) and (d) Here insert Full Name and Address of Company Official authorised to make claration.

) flere insert Basic ountry followed by date Basic Application.

(f) Here insert Full Name(s) of Applicant(s) in Basic Country.

by.....

In.

(g) Here Insert (in full) Name and Address of actual Inventor or Inventors.

(hereinafter referred to as "Applicant") for a patent for an invention entitled:	
(b)	
1 () Christine A. Trautwein, Assistant Secret	ary
of (d) 2800 Plymouth Road, Ann Arbor, Michigan 48105	U.S.A,
do solemnly and sincerely declare as follows:	
1. I am authorised by Applicant to make this declaration on its behalf.	
2. The basic Application(s) as defined by section 141 of the Act WAS / v	
in ^(e) U.S.Aon the24thday ofOctober	
by ⁽⁾ ThomasCharlesMaloneandJagadishChandraS	ircar
In	
byThomasCharlesMaloneandJagadishChandraS	ircar
Inday of	19

by..... ************

3. (0) Thomas Charles Malone ... 42337 Carriage Cove Circle Canton, Michigan 48187, U.S.A.Jayadish Chandra Sircar, 3615 Charter Place. Ann Arbor, Michigan 48105, U.S.A.xis/are

the actual Inventor(s) of the invention and the facts upon which Applicant is entitled to make the Application are as follows:


See reverse side of this form for guidance in completing this part.

APPLICANT IS THE ASSIGNEE OF THE SAID INVENTORS

4. The basic Application(s) referred to in paragraph 2 of this Declaration was/were the first Application(s) made in a Convention country in respect of the invention, the subject of the Application.

DECLARED a	Ann Arbor, Michigan, U.S.A.	•
this3rd		

(54)	Title 7-DEAZAGUANINES AS IMMUNOMODULATORS
(51)⁴	International Patent Classification(s) C07D 487/04 C07D 209/00 C07D 239/42 A61K 031/505
(21)	Application No.: 83281/87 (22) Application Date: 19.10.87
(87)	PCT Publication Number : WO88/03142
(30)	Priority Data
(31)	Number(32)Date(33)Country92352124.10.86US UNITED STATES OF AMERICA08623120.38.87US UNITED STATES OF AMERICA
(43)	Publication Date : 25.05.88
(44)	Publication Date of Accepted Application : 19.09.91
(71)	Applicant(s) WARNER-LAMBERT COMPANY
(72)	Inventor(s) THOMAS C. MALONE; JAGADISH C. SIRCAR
(74)	Attorney or Agent SHELSTON WATERS , 55 Clarence Street, SYDNEY NSW 2001
(56)	Prior Art Documents AU 14398/88 C07H 019/04 019/24 C07D 487/04 AU 77416/87 C07D 487/04 239/48 409/06
(57)	Claim



wherein R_6 is OH or SH, R_2 is hydrogen or NH₂, R_7 and R_8 are independently hydrogen or NH₂ with the proviso that both cannot be NH₂ at once, n is an integer of from one through four, Ar is (i) phenyl unsubstituted or substituted by halogen, trifluoromethyl, alkyl of one to four carbon atoms, hydroxy or alkoxy of from one to four carbon atoms, (ii) 2- or 3-thienyl, or (iii) 2- or 3-furanyl, with the proviso that when R_6 is OH, R_2 is H_2N , and R_7 and R_8 are both hydrogen then Ar cannot be phenyl when n is 1; or a pharmaceutically acceptable base or acid addition salt thereof.

I.

.../2


(11) AU-B-83281/87 (10) 614947

8. A method for treating autoimmune disease or rejection of transplantation which comprises administering a composition of Claim 7 in unit dosage form.

-2-

9. A method for treating psoriasis which comprises administering a composition of Claim 7 in unit dosage form.

	₩ - ₩	3281/87
PCT WORLD INTER INTERNATIONAL APPLICATION PUBLI	Inter	PROPERTION IZATION PROPERTION TREATY (PCT)
51) International Patent Classification ⁴ : C07D 487/04, A61K 31/505 C07D 239/42 // (C07D 487/04 C07D 239:00, 209:00)	A2	(11) International Publication Number:WO 88/ 0314(43) International Publication Date:5 May 1988 (05.05.8
21) International Application Number:PCT/22) International Filing Date:19 October 198	US87/027	2800 Plymouth Road, Ann Arbor, MI 48105 (US) et al.
31) Priority Application Numbers:	923,5 086,2	1 CG (OAPI patent), CH (European patent), CM (OAPI p
32) Priority Dates: 24 October 198 20 August 198	7 (20.08.)	 (European patent), JP, KP, KR, LK, LU (European paten MC, MG, ML (OAPI patent), MR (OAPI patent), MW, N
33) Prierity Country: 60) Parent Applications or Grants		S (European patent), NO, RO, SD, SÈ (European patent), S (OAPI patent), SU, TD (OAPI patent), TG (OAPI paten US, US,
(63) Related by Continuation US 923 Filed on 24 October 198	,231 (CO	 Without international search report and to be republished u on receipt of that report.
71) Applicant (for all designated States except US): LAMBERT COMPANY [US/US]; 2800 Plymo Ann Arbor, MI 48105 (US).	WARNE outh Roa	AUSTRALIAN 2 5 MAY 1988
 72) Inventors; and 75) Inventors/Applicants (for US only): MALONE, [US/US]; 42337 Carriage Cove Circle, Canton, (US). SIRCAR, Jagadish, C. [US/US]; 3615 Ch Ann Arbor, MI 48105 (US). 	Thomas, MI 481 arter Pla	PATENT OFFICE
		A.O.J.P. 2 3 JUN 1988



(1)

(57) Abstract


۱

Various 7-deazaguanines of formula (I), wherein R_6 is OH or SH, R_2 is hydrogen or NH₂, R_7 and R_8 are hydrogen or NH₂, n is an integer of from one through four, Ar is (i) phenyl unsubstituted or substituted by halogen, trifluoromethyl, alkyl, hydroxy or alkoxy, (ii) 2- or 3-thienyl, or (iii) 2- or 3-furanyl; having activity as immunomodulators. Also included are pharmaceutical compositions and methods of use thereof.

BACKGROUND OF THE INVENTION

-1-

The pyrrolo[2,3-d]pyrimidin-4-ones of the following formula 2, 3 and 4



2, R is $n-C_3H_7$ 3, R is $CH_2C_6H_5$ 4, R is cyclopentyl

are known. R.K. Robins, et al, synthesized the compounds of formula 2 and 3 as reported in <u>J. Het. Chem.</u>, 1964, 34, but gave no biological activity for either compound. M. Legraverend, et al, reported the synthesis of the compounds of formula 3 and 4 in <u>Tetrahedron Letters</u>, 1985, 2001, but again gave no biological activity for either compound.

Of lesser interest the following references provide a background in which a 7-(substituted phenyl)pyrrolo[2,3-d] pyrimidin-4-one having a methyl at each of the five (5) and six (6) positions for treating CNS illnesses or inflammations is disclosed generically in US Patent No. 4,229,453. Similarly, 4-mercapto-7-(phenyl substituted or unsubstituted)pyrrollo [2,3-d]pyrimidine derivatives requiring an alkyl or phenyl at the five (5) and six (6) positions are disclosed in German 3145287 (Derwent Abstract No. 49344 K/21). Other pyrrolo [2,3-d]pyrimidin-4-one or thione, distinguished by having

20

15

••••10

5


THENT OFFICE

various substituents at the five (5) position, are found in US
Patent No. 4,435,570 and 4,140,851; European publications
160,910 (Derwent Abstract No. 85-284574/46); 89,055
(corresponding to US Patent No. 4,571,423); 119,591 (Derwent
Abstract No. 84-238735/39); 79,447 (corresponding to US Patent
No. 4,435,569); German 3,306-390 (Derwent Abstract No. 39438
E/20); German 3145287 (Derwent Abstract No. 49344 K/21);
British Patent No. 981,458 (Derwent Abstract No. 15,454);
Japanese J6 0204,788 (Derwent Abstract No. 85/298810/48); and
Japanese J5 9036615 (Derwent Abstract No. 84-086061/84).

Finally, hydroxy and mercapto analogs of the antibiotic sparsomycin A are pyrrolo[2,3-d]pyrimidin-4-one or thione having a sugar moiety in the seven (7) position are disclosed by Upjohn in Netherlands 6,407,785 (Derwent Abstract No. 15,466) and similarly by Warner Lambert in European publication 57,548 (Derwent Abstract No. 68572 E/33).

Copending Applications Serial Number PD-3557 and Serial Number 767,202 filed August 22, 1985, now pending, which is a continuation-in-part of US Serial No. 660,152 filed October 12, 1984, now abandoned, disclose similar activity as now found in the present invention for different ring systems.

The present invention relates to a compound of the formula (I)



Τ

.

25

5

10

20


.....



-2-

wherein R_6 is OH or SH, R_2 is hydrogen or NH₂, R_7 and R_8 are independently hydrogen or NH₂ with the proviso that both cannot be NH₂ at once, n is an integer of from one through four, Ar is (i) phenyl unsubstituted or substituted by halogen, trifluoromethyl, alkyl of one to four carbon atoms, hydroxy, or alkoxy of from one to four carbon atoms, (ii) 2- or 3-thienyl, or (iii) 2- or 3-furanyl with the proviso that when R_6 is OH, and R_2 is H_2N , and R_7 and R_8 are both hydrogen then Ar cannot be phenyl when n is 1; or a pharmaceutically acceptable base or acid addition salt thereof.

The present invention also includes methods of manufacturing and novel intermediates therein, and a pharmaceutical composition for treating autoimmune diseases such as arthritis, systemic lupus erythematosus, inflammatory bowel diseases, juvenile diabetes, myasthenia gravis, multiple sclerosis, gout and gouty arthritis, as well as psoriasis, viral infections and cancer, or rejection of transplantation, comprising an anti-psoriatic, immunomodulator or antirejection effective amount such as an advantageously cytotoxic to T-cell amount, of a compound of the formula (I)



T.

or a pharmaceutically acceptble base or acid addition salt thereof wherein R_6 is OH or SH, R_2 is hydrogen or NH₂, R_7 and R_8 are independently hydrogen and NH₂ with the proviso that both cannot be NH₂ at once, n is an integer of from one to four, Ar is (i) phenyl unsubstituted or substituted by halogen, trifluoromethyl, alkyl of one to four carbon atoms, hydroxy, alkoxy of from one to four carbon atoms, (ii) 2- or 3-thienyl,

-3-

25

5

10

20

• • • • • •

WO 88/03142

PCT/US87/02727

Х

or (iii) 2- or 3-furanyl with a pharmaceutically acceptable carrier. Thus, the invention is also a method of treating psoriasis, an autoimmune disease, such as is listed above, or rejection of transplantation comprising administering to a host, such as a mammal including a human, suffering from psoriasis, the autoimmune disease or rejection of transplantation comprising administering an effective amount; i.e. an amount advantageously affecting T-cells by toxicity thereto, of a pharmaceutical composition of the formula I as defined above in unit dosage form. It is understood, an ordinarily skilled physician would begin treatment with a less than effective amount and increase the dose until the desired effect is obtained exercising care to administer an amount less than the amount toxic to the host of the disease.


-4-

15

10

5

The novel intermediates of the present invention are compounds of formula (X)




The method of manufacture of the present invention is a novel process for the preparation of a compound of the formula I as defined above; which comprises treating a compound of the formula (X)

-5- PD-3561-C1

X

v



with a compound of the formula (V)

 $\begin{pmatrix} NH_2 \\ | \\ (CH_2)_n \\ | \\ Ar \end{pmatrix}$

wherein Ar and n are as defined above and then treating with an acid to obtain the compound of formula I wherein R_6 is oxygen and R_8 is NH₂ and alternatively, if desired, further deaminating by known methods or treating also by known methods, to obtain a compound of formula I wherein R_6 is sulfur and then, if desired, deaminating.

The compound of formula X is prepared by treating a compound of the formula (IX)




WO 88/03142

5

10

PCT/US87/02727



-6-

with a cyanation agent, such as O,N-bistrifluoroacetylhydroxylamine, in the presence of a base, such as pyridine to obtain the compound of formula X.

H_N


The above preparations use standard synthetic techniques or techniques as shown or similar to those as shown in the examples hereinafter. The starting materials for the preparation are readily available, known or can be prepared by known methods.


The methods of manufacture for the compounds of the present invention are summarized in the following Schemes I and II.

IX

Scheme I


-7-





-8-

Scheme II



wherein R_2 is NH_2 , R_6 is O, R_7 is NH_2 and R₈ is hydrogen



5

10

15

20

25

30

PCT/US87/02727

Under certain circumstances it may be necessary to protect either the N or O of intermediates in the above noted process with suitable protecting groups which are known. Introduction and removal of such suitable oxygen and nitrogen protecting groups are well-known in the art of organic chemistry; see for example, (1) "Protective Groups in Organic Chemistry," J. F. W. McOmie, ed., (New York, 1973), pp 43ff, 95ff; (2) J. F. W. McOmie, <u>Advances in Organic Chemistry</u>, Vol. 3, 191-281 (1963); (3) R. A. Borssonas, <u>Advances in Organic Chemistry</u>, Vol. 3, 159-190 (1963); and (4) J. F. W. McOmie, <u>Chem. & Ind.</u>, 603 (1979).

-9-

Examples of suitable oxygen protecting groups are benzyl, t-butyldimethylsilyl, methyl, isopropyl, ethyl, tertiary butyl, ethoxyethyl, and the like. Protection of an N-H containing moiety is necessary for some of the processes described herein for the preparation of compounds of this invention. Suitable nitrogen protecting groups are benzyl, triphenylmethyl, trialkylsilyl, trichloroethylcarbamate,

trichloroethoxycarbonyl, vinyloxycarbamate, and the like,

Under certain circumstances it is necessary to protect two different oxygens with dissimilar protecting groups such that one can be selectively removed while leaving the other in place. The benzyl and t-butyldimethylsilyl groups are used in this way; either is removable in the presence of the other, benzyl being removed by catalytic hydrogenolysis, and t-butyldimethylsilyl being removed by reaction with, for example, tetra-n-butylammonium fluoride.

In the process described herein for the preparation of compounds of this invention the requirements for protective groups are generally well recognized by one skilled in the art of organic chemistry, and accordingly the use of appropriate protecting groups is necessarily implied by the processes of the charts herein, although not expressly illustrated.

The products of the reactions described herein are isolated by conventional means such as extraction, distillation, chromatography, and the like.

PCT/US87/02727 ·


-10-

The salts of compounds of formula I described above are prepared by reacting the appropriate base with stoichometric equivalent of the acid compounds of formula I to obtain pharmacologically acceptable salts thereof.

The compounds of this invention may also exist in hydrated or solvated forms.

DETAILED DESCRIPTION

The compounds of formula I of the present invention exist in tautomeric forms as purines or guanines as illustrated below. Both forms are included as part of the invention and are indiscriminately described in the specification.



The term "alkyl of one to four carbon atoms" means a straight or branched hydrocarbon chain up to four carbon atoms such as, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, secondary butyl or tertiary butyl. Alkoxy of one to four carbon atoms includes methoxy, ethoxy, propoxy, butoxy and isomers thereof. Halogen is fluorine, chlorine, bromine, or iodine.

20

25

15

The compounds of formula I are useful both in the free base form, in the form of base salts where possible, and in the form of acid addition salts. The three forms are within the scope of the invention. In practice, use of the salt form amounts to use of the base form. Appropriate pharmaceutically acceptable salts within the scope of the invention are those derived from mineral acids such as hydrochloric acid and

10

-11-

sulfuric acid, and organic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonate, and the like, respectively, or those derived from bases such as suitable organic and inorganic bases. Examples of suitable inorganic bases for the formation of salts of compounds of this invention include the hydroxides of ammonia, sodium, lithium, potassium, calcium, magnesium, aluminum, zinc, and the like.

Salts may also be formed with suitable organic bases. Bases suitable for the formation of pharmaceutically acceptable base addition salts with compounds of the present invention include organic bases which are nontoxic and strong enough to form such salts. These organic bases form a class whose limits are readily understood by those skilled in the art. Merely for purposes of illustration, the class may be said to include mono-, di-, and trialkylamines, such as methylamine, dimethylamine, and triethylamine; mono-, di-, or trihydroxyalkylamines such as mono-, di-, and triethanolamine; amino acids such as arginine, and lysine; guanidine; N-methylglucamine; L-glutamine; N-methylpiperazine; morpholine; ethylenediamine; N-benzylphenethylamine; tri(hydroxymethyl)aminomethane; and the like. (See for example, "Pharmaceutical Salts," J. Pharm. Sci. (1977) 66(1):1-19,)

The acid addition salts of said basic compounds are prepared either by dissolving the free base of compound I in aqueous or aqueous alcohol solution or other suitable solven containing the appropriate acid or base and isolating the salt by evaporating the solution, or by reacting the free base of compound I with an acid as well as reacting compound I having an acid group thereon with a base such that the reactions are in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.

A preferred embodiment of the present invention is a compound of formula I wherein R_6 is OH or SH; R_2 and R_8 are NH₂, n is one, and Ar is 2- or 3-thienyl. A more preferred embodiment is 2-amino-7-(2-thienylmethyl)-4-pyrrolo[2,3-d)] pyrimidone.

10

5

15

20

25

30

-12-

The compositions having compounds of the formula I of the present invention are shown to exhibit significant enzyme inhibition activity and cytotoxicity activity. In the purine nucleoside phosphorylase (PNP-4) enzyme assay, an IC_{50} is achieved at a dose of 1.0 micromoles on a selected compound of the present invention. PNP-4 activity for the compound of formula I is measured radiochemically by measuring the formation of [¹⁴-C]hypoxanthine from [¹⁴-C]inosine [Biomedicine, <u>33</u>, 39 (1980)] using human erythrocyte as the enzyme source.

It is known that an in vivo inhibition of purine nucleoside phosphorylase (HPLC-1) enzyme assay may also be used essentially as disclosed in the Annals of New York Academy of Sciences, Volume 451, Page 313 (1985) to further show the activity for compositions of the compounds of formula I of the present invention. The present invention compositions also are generally shown by a standard test (HTBA-1) [Science, 214, 1137, (1981)] to be selectively cytotoxic for T-cells in the presence of 2'-deoxyguanosine at a similar concentration range and nontoxic to B-cell in the presence of the same amount of 2'-deoxyguanosine by the compound of Example 2, thus demonstrating utility for the compounds of formula I in pharmaceutical compositions as described herein. Since PNP inhibition and removal of T-cells or modulation of T-cells are known to be characteristics of compounds beneficial in the treatment of psoriasis, rejection phenomenon in transplantation, and autoimmune diseases, the present invention compositions of compounds being selectively cytotoxic to T-cells and being PNP inhibitors will, therefore, also be useful in such treatment. For example, 8-Aminoguanosine, a known PNP-inhibitor, has been shown to be efficacious for inhibiting rejection of skin graft in dogs [J. B. Benear, et al, Transplantation, 1986, 41:274]. Clinically it has been shown that modulation and/or removal of T-dells by thoracic duct drainage, lymphapheresis or total lymphoid irradiation gave partial to complete relief from rheuma bid arthritis in patients who were totally refractory to other forms of therapy

.

20

25

15

5

10

30

-13-

(A. Tanay, et al, Arthritis and Rheumatism, Vol. 30, No. 1, p. 1 (1987). S. Strober, et al, Annual of Internal Medicine, V-102, No. 4, 441-449 (1985); H. G. Nusslein, et al, Arthritis and Rheumatism, V-28, No. 11, 1205-1210 (1985); E. Brahn, et al, ibid, V-27, No. 5, 481-487 (1984), and J. Karsh, et al, ibid, V-24, No. 7, 867-873 (1981)). Cyclosporin A, a T-cell modulator, showed beneficial effects in the treatment of juvenile diabetes. (A. Assan, et al, The Lancet, January 12, p. 67 (1985).) Additionally, cyclosporin A is presently the drug of choice for the prevention of transplant rejection, (R. M. Merion, et al, New Eng. J. Med., (1984) 148). More recently, cyclosporin A is shown to be useful to treat psoriasis. Further, it is suggested the cyclosporin therapy is shown to markedly reduce activated T-cells in psoriatic Therefore, it is reasonable to believe the basis of lesions. the successful treatment of psoriasis is modulation of T-cell activity as shown by compounds in the present invention composition. (See C. N. Ellis, et al, JAMA, V-256, No. 22, Dec. 12, 1986, pp. 3110-3116.) Finally, cyclosporin A is shown to be efficacious in rheumatoid arthritis. (M. E. Weinblatt, et al, Arthritis and Rheumatism, V-30, No. 1, pp. 11-17 (January, 1987); O. Forre, et al, Arthritis and Rheumatism, V-30, No. 1, pp. 88-92 (January, 1987); M. Dougados, et al, Arthritis and Rheumatism, Vol. 30, No. 1, pp. 83-87 (January, 1987).

Representative examples from the present invention are shown in the following activity table to provide the activity discussed above.

10

5

15


20

2.5

PCT/US87/02727.

-14-

ACTIVITY TABLE



	2'-d Gua; IC ₅₀ μM
2 H H 2-Th 1.	0 2.3

Th = Thiophene

In vivo studies based on the above noted disclosures may be used to determine activity in the particular disease states noted.

Since T-cells play a central role in immune response, use of the compounds of the invention is contemplated for the immunoregulation to prevent rejection in transplantation or in the treatment of psoriasis and in the treatment of autoimmune disease such as rheumatoid arthritis, systemic lupus erythrematosus, inflammatory bowel disease, multiple sclerosis, myasthemia gravis, gout or gouty arthritis, juvenile diabetes, cancer, and viral diseases. The present invention thus includes compositions containing a compound of formula I in treating rejection of transplantation or disease such as psoriasis in humans or autoimmune disease characterized by abnormal immune response in primates or humans. According to this aspect of the invention, the properties of the compounds of the invention are utilized by administering to a warmblooded animal an effective amount of a pharmaceutical composition

15

10

5

25

-15-

containing as the active ingredient at least about 0.1 percent by weight, based on the total weight of the composition of at least one such compound of the invention.

Pharmaceutical compositions of the invention can be formulated in any suitable way, preferably with an inert carrier for administration orally, parenterally, ophthalmically, topically, or by suppository.

For example, the compounds of the present invention are formulated into dosage forms such as tablets or syrups by blending with an inert pharmaceutical carrier such as lactose or simple syrup by methods well-known in the art. For injectable dosage forms, they are formulated with vehicles such as water, propylene glycol, peanut oil, sesame oil, and the like. In these dosage forms, the active ingredient is from about 0.05 grams to 0.5 grams per dosage unit.

The present invention is further illustrated by way of the following examples.

Example 1

2-Amino-6-[(2-thienylmethyl)amino]-4-pyrimidinol

2-Amino-6-chloro-4-pyrimidinol, monohydrate (85%, 100 g, 0.5197 mol) was suspended in methoxyethanol (700 ml) and 2-thienylmethylamine (96%, 61.3 g, 0.5197 mol) was added to the suspension. The mixture was heated under reflux for two hours and then 73 ml (d = 0.726; 0.52 mol) of triethylamine was added and the refluxing continued for an additional 18 hours. The reaction mixture was poured into ice water (1000 ml), acidified with acetic acid (ph 4.0) and the precipitated solid was filtered, washed, and dried. Yield: 110 g (72.6%). This was used in the next step without further purification.

Example 2

2-Amino-7-(2-thienylmethyl)-4-pyrrolo[2,3-d]pyrimidones

Chloroacetaldehyde dimethyl acetal (14 ml) was added to water (50 ml) and concentrated HCl (2.0 ml). The mixture was heated at reflux temperature for 30 minutes and then

20

25

30

5

10

neutralized with sodium acetate (10 g). The resulting solution was added in one portion to a mixture of 2-amino-4-(2-thienylmethylamino)-6-pyrimidone (10 g; 45 mmol), sodium acetate (5.0 g) and hot water (50 ml). The mixture was allowed to stir on a steam bath (80°C) for 30 minutes, and the precipitated solid was filtered, washed with water, and dried in vacuo. The crude product was dissolved in methanol and concentrated HCl and treated with charcoal to remove coloring matter. The product (3.2 g) thus obtained was recrystallized from methanol and 1N HCl (100 ml) to give 1.68 g (13.5%) of the desired product as light brown solid, mp 243-245°C (dec).

2-Amino-4-chloro-6-[2-thienylmethyl)amino]-5-(2,2-diethoxyethyl)pyrimidine

A solution of 2-amino-4,6-dichloro-5-(2,2diethoxyethyl) pyrimidine (M. Legraverend, et al, <u>J. Med.</u> <u>Chem.</u>, 1985, 28:1477) (906 mg, 3.20 mmol) in 40 ml of n-butanol containing Et_3N (1ml) and 2-thienylmethylamine (425 mg, 3.75 mmol) was heated at 100°C for 48 hours. The reaction mixture was cooled to 25°C and concentrated. The residue was purified by column chromatography over silica gel and eluted with chloroform to give the desired product (1.045 g) (91.5%) as a yellow oil.

2-Amino-4-chloro-7-(2-thienylmethyl)pyrrolo[2,3-d]pyrimidine

A suspension of 2-amino-4-chloro-6-[(2-thienylmethyl) amino]-5-(2,2-diethoxyethyl)pyrimidine (1.0 g, 2.80 mmol) in 65 ml of 0.3N HCl and ethanol (2.25:1) was stirred at 25°C for 24 hours. The reaction mixture was neutralized with ammonium hydroxide solution and the product collected



5

10

20

25



-

by filtration. TLC analysis showed that the reaction was not complete, so, the product was resuspended in 50 ml of 0.2N HCl and stirred for 48 hours. The reaction mixture was neutralized with NH_4OH solution and concentrated. The residue was taken up in water and then evaporated to dryness to give yellow solid (573 mg) (77.3%). This was used in the next step without further purification.

5


-17-

2-Amino-7-(2-thienylmethyl)-4-pyrrolo[2,3-d]pyrimidone

2-Amino-4-chloro-7-(2-thienylmethyl)pyrrolo[2,3-d] pyrimidine (563 mg, 2.10 mmol) was suspended in 30 ml of 1N HCl and ethanol (1:1) and the mixture was heated at reflux for 8 hours. Removal of solvent gave a residue which was chromatographed over silica gel and eluted with a mixture of hexane-ethyl-acetate (10:1) to give 139 mg of a mixture of 4-chloro and 4-ethoxy derivatives. So, it was dissolved in 30 ml of 3N HCl and the solution was heated to reflux for 2 hours and then allowed to cool. The precipitated solid was filtered and then recrystallized from methanol - 1N HCl (1:1) mixture to give 55 mg of the desired product as hydrochloride salt, mp 235-237°C (dec).

10

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:-1. A compound of formula (I)



10

20

5

5

wherein R_6 is OH or SH, R_2 is hydrogen or NH_2 , R_7 and R_8 are independently hydrogen or NH_2 with the proviso that both cannot be NH_2 at once, n is an integer of from one through four, Ar is (i) phenyl unsubstituted or substituted by halogen, trifluoromethyl, alkyl of one to four carbon atoms, hydroxy or alkoxy of from one to four carbon atoms, (ii) 2- or 3-thienyl, or (iii) 2- or 3-furanyl, with the proviso that when R_6 is OH, R_2 is H_2N , and R_7 and R_8 are both hydrogen then Ar cannot be phenyl when n is 1; or a pharmaceutically acceptable base or acid addition salt thereof.

2. A compound of Claim 1 wherein R_7 is hydrogen.

3. A compound of Claim 2 wherein R_8 is hydrogen.


4. A compound of Claim 2 wherein R₈ is amino.

5. A compound of Claim 3 and being 2-amino-7-(2-thienylmethyl)-4-pyrrolo[2,3-d]pyrimidone.

6. A compound of Claim 5 and being the hydrochloride salt thereof.

7. A pharmaceutical composition for treating psoriasis, autoimmune diseases or rejection of transplantation comprising an antipsoriatic, antiautoimmune disease or antirejection of transplantation effective amount of a compound of formula (I) or a pharmaceutically acceptable

Ι




I

X

base or acid addition salt thereof; wherein R_6 is OH or SH, R_2 is hydrogen or NH₂, R_7 and R_8 are independently hydrogen and NH₂ with the proviso that both can not be NH₂ at once, n is an integer of from one to four, Ar is (i) phenyl unsubstituted or substituted by halogen, trifluoromethyl, alkyl of one to four carbon atoms, hydroxy, alkoxy of from one to four carbon atoms, (ii) 2- or 3-thienyl, or (iii) 2- or 3-furanyl and a pharmaceutically acceptable carrier.

8. A method for treating autoimmune disease or rejection of transplantation which comprises administering a composition of Claim 7 in unit dosage form.

9. A method for treating psoriasis which comprises administering a composition of Claim 7 in unit dosage form. 10. A process for preparing a compound of formula I as defined in claim 7 which comprises treating a compound of the formula (X)





10

with a compound of the formula (V)

NH₂ Ar-

wherein Ar and n are as defined above and then treating with an acid to obtain the compound of formula I wherein R_6 is oxygen and R_8 is NH_2 and, alternatively, if desired, further deaminating by known methods, or treating by also known methods to obtain a compound of formula I wherein R_6 is sulfer and then, further deaminating.

- 20 -

۷

DATED THIS 9TH DAY OF JULY 1991 WARNER-LAMBERT COMPANY

> Attorney: WILLIAM S. LLOYD Fellow Institute of Patent Attorneys of Australia of SHELSTON WATERS



4

10

15

• • • • •

INTERNATIONAL SEARCH REPORT

۰ 			PCT/US 87/027
	IFICATION OF SUBJECT MATTER (If several classi		
According 4	to International Patent Classification (IPC) or to both Nat C 07 D 487/04; A 61 K $31/5$	05; C 07 D 239/42;	/(C 07 D 487/04
IPC :	239:00,209:00)		
II. FIELD	SEARCHED	in an an ann an an an an an an an an an a	
	Minimum Documer	ntation Searched ?	
lassificatio	on System	Classification Symbols	
IPC ⁴	C 07 D 487/00; A 6	1 K 31/00; C 07 D	239/00
	Documentation Searched other t to the Extent that such Documents	han Minimum Documentation are included in the Fields Searched *	
	MENTS CONSIDERED TO BE RELEVANT		Relevant to Claim No. 13
alegory •	Citation of Document, 11 with Indication, where app	White of the relevant bassages is	Pelevent to cigity up, is
X	Tetrahedron Letters, volu 1985, Pergamon Pres M. Legraverend et a to 7-deazaguanine d pages 2001-2002, se cited in the application	s Ltd (GB) 1.: "A new route erivatives",	
A	EP, A, 0156559 (WARNER-LA 1985, see claim 1; 11,12; page 8		1,7
A	FR, A, 2574407 (RHONE-POU see claim 1; page 5	LENC) 13 June 1986 , lines 26-31	. 1,7
"A" docu cons "E" earlie nling "L" docu whic citati "O" docu other "P" docu later	categories of cited documents: 10 ment defining the general state of the art which is not idered to be of particular relevance or document but published on or after the international date ment which may throw doubts on priority claim(s) or his cited to establish the publication date of another on or other special reason (as specified) ment referring to an oral disclosure, use, exhibition or means ment published prior to the international filing date but than the priority date gleimed FICATION	 "T" later document published after i or priority date and not in conflicted to understand the principi invention. "X" document of particular relevan cannot be consider:" novel of involve an inventive step "Y" document of particular relevan cannot be considered to involve document is combined with one m(ints, such combination being in the art. "A" document member of the same 	Ict with the application but e of theory underlying the cel the claimed invention cannot be considered to cel the claimed invention an inventive step when the of more other such docu- obvious to a person skilled patent family
	Actual Completion of the International Search ch. February 1988	Bate of Mailing of this International Se	26 APR 1988
ternationa	Searching Authority EUROPEAN PATENT OFFICE	Signature of Author/200 Officer	AN DER PUTTEN

UNTHER INFORMATION CONTINUED FROM THE SECOND SHEET				. 4 . − 1	Intern	ational Applicatio	n No. PC	C/US 87/C)2727
In International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons: Claim numbers, 3, 9, because they relate to subject matter not required to be searched by this Authority, namely: See PCT-Rule 39.1 (iv): methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods. Claim numbers	FURTHE	RINFORMATI	ON CONTINUES	FROM THE	SECOND SHE	EŢ		مود کلیک و در اور اور اور اور	
In International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons: Claim numbers, 3, 9, because they relate to subject matter not required to be searched by this Authority, namely: See PCT-Rule 39.1 (iv): methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods. Claim numbers								it its a supportant solution	
In International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons: Claim numbers, 3, 9, because they relate to subject matter not required to be searched by this Authority, namely: See PCT-Rule 39.1 (iv): methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods. Claim numbers									
In International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons: Claim numbers, 3, 9, because they relate to subject matter not required to be searched by this Authority, namely: See PCT-Rule 39.1 (iv): methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods. Claim numbers		4 ¹							(1,2,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,3,
International search report has not been established in respect of certain claims under Article 17(2) (a) for the following researce: Claim numbers, 3, 9, because they relate to subject matter not required to be searched by this Authority, namely: See PCT-Rule 39.1 (iv): methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods. Claim numbers,, because they relate to parts of the international application that do not comply with the prescribed require ments to such an estant that no meaningful international search can be certified out, specifically: Claim numbers,, because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 5.4(a). Li OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ² International Searching Authority found multiple inventions in this international application as follows: As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application for which less were paid, specifically claims: No required additional search fees were it: aly paid by the applicant. Consequently, this international search report is restricted to the international application for which less were paid, specifically claims: No required additional search fees were it: aly paid by the applicant, this international search report is restricted to the international application for which less were paid, specifically claims: No required additional search fees were it: aly paid by the applicant, this international search report is restricted to the international application for which less were paid, specifically claims: As any source additional search fees were it: aly paid by the applicant, this international search report is restricted to the international application for which less were paid, specifically claims: As a distand applica		1						1	
International search report has not been established in respect of certain claims under Article 17(2) (a) for the following researce: Claim numbers, 3, 9, because they relate to subject matter not required to be searched by this Authority, namely: See PCT-Rule 39.1 (iv): methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods. Claim numbers,, because they relate to parts of the international application that do not comply with the prescribed require ments to such an estant that no meaningful international search can be certified out, specifically: Claim numbers,, because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 5.4(a). Li OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ² International Searching Authority found multiple inventions in this international application as follows: As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application for which less were paid, specifically claims: No required additional search fees were it: aly paid by the applicant. Consequently, this international search report is restricted to the international application for which less were paid, specifically claims: No required additional search fees were it: aly paid by the applicant, this international search report is restricted to the international application for which less were paid, specifically claims: No required additional search fees were it: aly paid by the applicant, this international search report is restricted to the international application for which less were paid, specifically claims: As any source additional search fees were it: aly paid by the applicant, this international search report is restricted to the international application for which less were paid, specifically claims: As a distand applica		- · ·						ç.	
 International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons: Claim numbers. 3, 9, because they relate to subject matter not required to be searched by this Authority, namely: See PCT-Rule 39.1 (iv): methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods. Claim numbers								l.	
International search report has not been established in respect of certain claims under Article 17(2) (a) for the following researce: Claim numbers, 3, 9, because they relate to subject matter not required to be searched by this Authority, namely: See PCT-Rule 39.1 (iv): methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods. Claim numbers,, because they relate to parts of the international application that do not comply with the prescribed require ments to such an estant that no meaningful international search can be certified out, specifically: Claim numbers,, because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 5.4(a). Li OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ² International Searching Authority found multiple inventions in this international application as follows: As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application for which less were paid, specifically claims: No required additional search fees were it: aly paid by the applicant. Consequently, this international search report is restricted to the international application for which less were paid, specifically claims: No required additional search fees were it: aly paid by the applicant, this international search report is restricted to the international application for which less were paid, specifically claims: No required additional search fees were it: aly paid by the applicant, this international search report is restricted to the international application for which less were paid, specifically claims: As any source additional search fees were it: aly paid by the applicant, this international search report is restricted to the international application for which less were paid, specifically claims: As a distand applica								ĺ	
 International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons: Claim numbers. 3, 9, because they relate to subject matter not required to be searched by this Authority, namely: See PCT-Rule 39.1 (iv): methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods. Claim numbers	н							l ·	
 International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons: Claim numbers. 3, 9, because they relate to subject matter not required to be searched by this Authority, namely: See PCT-Rule 39.1 (iv): methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods. Claim numbers									
 International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons: Claim numbers. 3, 9, because they relate to subject matter not required to be searched by this Authority, namely: See PCT-Rule 39.1 (iv): methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods. Claim numbers		I						8	
 International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons: Claim numbers. 3, 9, because they relate to subject matter not required to be searched by this Authority, namely: See PCT-Rule 39.1 (iv): methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods. Claim numbers	.							į	
International search report has not been established in respect of certain claims under Article 17(2) (a) for the following researce: Claim numbers, 3, 9, because they relate to subject matter not required to be searched by this Authority, namely: See PCT-Rule 39.1 (iv): methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods. Claim numbers,, because they relate to parts of the international application that do not comply with the prescribed require ments to such an estant that no meaningful international search can be certified out, specifically: Claim numbers,, because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 5.4(a). Li OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ² International Searching Authority found multiple inventions in this international application as follows: As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application for which less were paid, specifically claims: No required additional search fees were it: aly paid by the applicant. Consequently, this international search report is restricted to the international application for which less were paid, specifically claims: No required additional search fees were it: aly paid by the applicant, this international search report is restricted to the international application for which less were paid, specifically claims: No required additional search fees were it: aly paid by the applicant, this international search report is restricted to the international application for which less were paid, specifically claims: As any source additional search fees were it: aly paid by the applicant, this international search report is restricted to the international application for which less were paid, specifically claims: As a distand applica	1.1	ан сайтан са Вайтан сайтан							
International search report has not been established in respect of certain claims under Article 17(2) (a) for the following researce: Claim numbers, 3, 9, because they relate to subject matter not required to be searched by this Authority, namely: See PCT-Rule 39.1 (iv): methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods. Claim numbers,, because they relate to parts of the international application that do not comply with the prescribed require ments to such an estant that no meaningful international search can be certified out, specifically: Claim numbers,, because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 5.4(a). Li OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ² International Searching Authority found multiple inventions in this international application as follows: As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application for which less were paid, specifically claims: No required additional search fees were it: aly paid by the applicant. Consequently, this international search report is restricted to the international application for which less were paid, specifically claims: No required additional search fees were it: aly paid by the applicant, this international search report is restricted to the international application for which less were paid, specifically claims: No required additional search fees were it: aly paid by the applicant, this international search report is restricted to the international application for which less were paid, specifically claims: As any source additional search fees were it: aly paid by the applicant, this international search report is restricted to the international application for which less were paid, specifically claims: As a distand applica		SEDVATIONS				NSFARCHARL	F 1		
 Claim numbers. 8, 9 because they relate to subject matter not required to be searched by this Authority, namely: See PCT-Rule 39.1 (iv): methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods. Claim numbers	and the state of t		kang kanalan sala ng	de de la la complete	ya kunta dan dara		an sa hisi s isisisi		
See PCT-Rule 39.1 (iv): methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.									ressons:
body by surgery or therapy, as well as diagnostic methods.									mal
diagnostic methods. Claim numbers	266	FUL MULC	, 92. - (44)						
ments to such an extent that no meaningful International search can be carried out, specifically: Claim numbers Claim numbers Claim numbers Decause they are dependent claims and are not dratted in accordance with the second and third sentences of PCT Rule 6.4(a). Claim numbers OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING 3 Image: Claim actional second fees were timely paid by the applicant, this international search report covers all searchable claims of the international application as follows: As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application. As only some of the required additional search fees were limely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims: No required additional search fees were it: jely paid by the applicant. Consequently, this international search report is restricted to the international in the claims; it is covered by claim numbers: As all searchable claims could be searched without effort justifying an additional fee, the international Searching Authority did not invite payment of any additional fee. As all searchable claims accould be searched without effort justifying an additional fee, the international Searching Authority did not invite payment of any additional fee.							•		
ments to such an extent that no meaningful International search can be carried out, specifically: Claim numbers Claim numbers Claim numbers Decause they are dependent claims and are not dratted in accordance with the second and third sentences of PCT Rule 6.4(a). Claim numbers OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING 3 Image: Claim actional second fees were timely paid by the applicant, this international search report covers all searchable claims of the international application as follows: As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application. As only some of the required additional search fees were limely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims: No required additional search fees were it: jely paid by the applicant. Consequently, this international search report is restricted to the international in the claims; it is covered by claim numbers: As all searchable claims could be searched without effort justifying an additional fee, the international Searching Authority did not invite payment of any additional fee. As all searchable claims accould be searched without effort justifying an additional fee, the international Searching Authority did not invite payment of any additional fee.									
ments to such an extent that no meaningful international search can be carried out, specifically: Claim numbers Claim numbers Claim numbers Decause they are dependent claims and are not dratted in accordance with the second and third sentences of PCT Rule 6.4(a). Image: Claim outpers Decause they are dependent claims and are not dratted in accordance with the second and third sentences of PCT Rule 6.4(a). Image: Claim outpers Descent outpers Image: Claim of the international application Descent outpers Image: Claim of the international application for which fees were paid, specifically claims: Descent outpers Image: Claim of the international application for which fees were paid, specifically claims: Descent outpers Image: Claim outpers Descent fees were it: sily paid by the applicant. Consequently, this international search report is restricted to the international search fees were it: sily paid by claim numbers: Image: Descent outpers			an the second	•					
ments to such an extent that no meaningful international search can be carried out, specifically: Claim numbers Claim numbers Claim numbers Decause they are dependent claims and are not dratted in accordance with the second and third sentences of PCT Rule 6.4(a). Image: Claim outpers Decause they are dependent claims and are not dratted in accordance with the second and third sentences of PCT Rule 6.4(a). Image: Claim outpers Descent outpers Image: Claim of the international application Descent outpers Image: Claim of the international application for which fees were paid, specifically claims: Descent outpers Image: Claim of the international application for which fees were paid, specifically claims: Descent outpers Image: Claim outpers Descent fees were it: sily paid by the applicant. Consequently, this international search report is restricted to the international search fees were it: sily paid by claim numbers: Image: Descent outpers									
PCT Rule 6.4(a). I. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ? I. Internetional Searching Authority found multiple inventions in this international application as follows: As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were timely paid, specifically claims? No required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims? No required additional search fees were timely paid by the applicant. Consequently, this international search report covers only the invention first mentioned in the claims; it is covered by claim humbers? As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee. As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee. The additional search fees were accompanied by applicant's protest.									
PCT Rule 6.4(a). I. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ? his International Searching Authority found multiple Inventions in this International application as follows: As all required additional search fees were timely paid by the applicant, this International search report Covers all searchable claims of the International application. As only some of the required additional search fees were timely paid by the applicant, this International search report covers only those claims of the International application for which fees were paid, specifically claims? No required additional search fees were timely paid by the applicant, this International search report covers only those claims of the International application for which fees were paid, specifically claims? No required additional search fees were timely paid by the applicant. Consequently, this International search report covers only those claims of the international application for which fees were paid, specifically claims? No required additional search fees were timely paid by the applicant. Consequently, this International search report is restricted to the Invention first mentioned in the claims; it is covered by claim humbers: As all searchable claims could be searched without effort justifying an additional (ee, the International Searching Authority did not invite payment of any additional fee. Invite payment of any additional fee. Invite payment of any additional fee. The additional search fees were accompanied by applicant's protest.									
PCT Rule 6.4(a). I. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING ? International Searching Authority found multiple inventions in this international application as follows: As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims! No required additional search fees were timely paid by the applicant. Consequently, this international search report covers only those claims of the international application for which fees were paid, specifically claims! No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim humbers: As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee. As all search fees were accompanied by applicant's protest.									
PCT Rule 6.4(a). I	Clain	n numbers	- Necalise they are	decendent claim	s and are not dr	afted in accordance	a with the sec	ond and third a	entences of
As all required additional search fees were timely paid by the applicant, this international application as follows: As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claimst No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim humbers; As all searchable claims could be searched without effort justifying an additional fee, the international Searching Authority did not invite payment of any additional fee, mark on Protest The additional search fees were accompanied by applicant's protest.			teres and the	aabar aanti samu				1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 -	
As all required additional search fees were timely paid by the applicant, this international application as follows: As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claimst No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim humbers; As all searchable claims could be searched without effort justifying an additional fee, the international Searching Authority did not invite payment of any additional fee, mark on Protest The additional search fees were accompanied by applicant's protest.		SERVATIONS	WURDE UNITY	OF INVENTIO	N IS LACKIN	c ł		and the second secon	Hereiter er filt der er
As all required additional search fees were timely paid by the applicant; this international search report Covers all searchable claims of the international application; As only some of the required additional search fees were timely paid by the applicant; this international search report covers only those claims of the international search fees were timely paid by the applicatly claims; No required additional search fees were timely paid by the applicant; this international search report covers only those claims of the international application for which fees were paid, specifically claims; No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim humbers; As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee; mark on Protest The additional search fees were accompanied by applicant's protest;									ga triding bargara .
 of the International application; As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international search report covers only those claims of the international search fees were ticlely paid by the applicant; this international search report covers only those claims of the international search fees were ticlely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim sumbers; As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee, mere accompanied by applicant's protest; The additional search fees were accompanied by applicant's protest; 	hie intern	ational Searchin	g Authority found	multiple inventio	ne in this intern	itional application	as (ollows:		
 of the International application; As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international search report covers only those claims of the international search fees were ticlely paid by the applicant; this international search report covers only those claims of the international search fees were ticlely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim sumbers; As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee, mere accompanied by applicant's protest; The additional search fees were accompanied by applicant's protest; 									
 of the International application; As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international search report covers only those claims of the international search fees were ticlely paid by the applicant; this international search report covers only those claims of the international search fees were ticlely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim sumbers; As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee, mere accompanied by applicant's protest; The additional search fees were accompanied by applicant's protest; 									
 of the international application. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international search report covers only those claims of the international search fees were tickly paid by the applicant, this international search report covers only those claims of the international search fees were tickly paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim sumbers; As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee. The additional search fees were accompanied by applicant's proteet. 					1				
As any some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims: No required additional search fees were tickly paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim humbers: As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee. mark on Protest The additional search fees were accompanied by applicant's protest.				re limely paid by	the applicant, th	la International se	arch report co	vers all search	able claims
the Invention first mentioned in the claims; it is covered by claim humbers; As all searchable claims could be searched without effort justifying an additional lee, the International Searching Authority did not invite payment of any additional lee, mark on Protest The additional search fees were accompanied by applicant's protest.	A	nly some of the r	required additional				International	search report	covers only
the Invention first mentioned in the claims; If is covered by claim numbers: As all searchable claims could be searched without effort justifying an additional lee, the International Searching Authority did not invite payment of any additional lee, emark on Protest The additional search lees were accompaniad by applicant's protest.									4 - A - 14
the Invention first mentioned in the claims; If is covered by claim numbers: As all searchable claims could be searched without effort justifying an additional lee, the International Searching Authority did not invite payment of any additional lee, emark on Protest The additional search lees were accompaniad by applicant's protest.		الاحتاد المالية المقاداته	l manak dala masa	Receive statistic da	a annihardt Öri	CARGE ALL ALL ALL ALL ALL ALL ALL ALL ALL AL	Arnational	148 14XAH 14 -	addising to
invite payment of any additional fee, omark on Protect The additional search fees were accompanied by applicant's protect.							aillen aller påd	ING INPOLLIN F	4 # WIG1 # Q: 1Q:
Invite payment of any additional lee. Invite on Protest The additional search lees were accompanied by applicant's protest.							2	1. A.	
The additional search fees were accompanied by applicant's protest.		searchable claim payment of any	is could be searchi additional fee,	ed without effort	justilying an ad	ditional lee, the I	nternational S	arching Autho	offy did not
		Protest	1						
	matk on								

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO. US

US 8702727 SA 19649

This samex fasts the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office ERP file on 18/04/88 The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0156559	02-10-85	AU-A- 4021985 JP-A- 60248690	03-10-85 09-12-85
FR-A- 2574407	13-06-86	None	

PO FORM P019

For more details about this annex t see Official Journal of the European Patent Office, No. 12/32